<DOC>
	<DOCNO>NCT02034552</DOCNO>
	<brief_summary>The primary objective study evaluate bone scan response Week 24 base quantified technetium-99 bone scan lesion area ( BSLA ) . The safety radium-223 dichloride combination abiraterone acetate enzalutamide investigate . The study evaluate radiological progression free survival , overall survival , skeletal event . This study also explore clinical utility different image modality ( whole body quantify technetium-99 bone scan , DW-MRI NaF PET-CT scan ) separate central radiological review applicable secondary exploratory image endpoint . All subject randomize assign randomly IXRS system 1:1:1 ratio one treatment arm : radium-223 dichloride alone , 50 kBq/kg ( 55 kBq/kg implementation NIST update ) every 4 week 6 dos ; radium-223 dichloride , 50 kBq/kg ( 55 kBq/kg implementation NIST update ) every 4 week 6 dos together abiraterone acetate 1,000 mg daily prednisone 5 mg bid ; radium-223 dichloride 50 kBq/kg ( 55 kBq/kg implementation NIST update ) every 4 week 6 dos together enzalutamide 160 mg daily.The study consist screening , treatment follow-up period . Study continue disease progression determine investigator , patient meet criteria withdrawal study . Subjects treatment arm abiraterone/prednisone enzalutamide option continue take oral study therapy end study ( 2 year last dose radium-223 dichloride ) investigator deems subject may benefit clinical radiological progression . Subjects discontinue study treatment prior 2 year last radium-223 dichloride treatment enter active follow-up . During active follow-up period , subject safety visit clinic every 12 week EOT 2 year last dose radium-223 dichloride . Beyond 2 year last radium-223 dichloride treatment , subject enter long-term follow-up follow via phone contact interval assess safety ( hematological toxicity new primary malignancy ) overall survival . A separate long-term safety follow-up study protocol plan . Once implement , study subject survive end active follow-up transition separate long-term safety follow-up protocol .</brief_summary>
	<brief_title>A Randomized Phase IIa Efficacy Safety Study Radium-223 Dichloride With Abiraterone Acetate Enzalutamide Metastatic Castration-resistant Prostate Cancer ( CRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Known castrationresistant disease Serum PSA ≥2 ng/mL ( μg/L ) Multiple skeletal metastasis ( ≥2 hot spot ) bone scan Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 . Life expectancy ≥6 month Adequate hematologic , hepatic , renal function History visceral metastasis , visceral metastasis Malignant lymphadenopathy lymph node exceed 3 cm short axis diameter Medical condition would make prednisone ( corticosteroid ) use contraindicate Any chronic medical condition require high dose corticosteroid 5 mg prednisone bid Treatment one chemotherapy agent prostate cancer Prior systemic radiotherapy hemibody external radiotherapy History pituitary adrenal dysfunction Chronic condition associate nonmalignant abnormal bone growth ( e.g. , confirm Paget 's disease bone ) Atrial fibrillation , cardiac arrhythmia require medical therapy History seizure ( taking/not take anticonvulsant ) , arteriovenous malformation brain , head trauma loss consciousness Central nervous system ( CNS ) metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>